Kaira Kyoichi, Oriuchi Noboru, Shimizu Kimihiro, Ishikita Tomohiro, Higuchi Tetsuya, Imai Hisao, Yanagitani Noriko, Sunaga Noriaki, Hisada Takeshi, Ishizuka Tamotsu, Kanai Yoshikatsu, Endou Hitoshi, Nakajima Takashi, Endo Keigo, Mori Masatomo
Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan.
Int J Cancer. 2009 Mar 1;124(5):1152-60. doi: 10.1002/ijc.24034.
L-[3-(18)F]-alpha-methyltyrosine ((18)F-FMT) is an aminoacid tracer for positron emission tomography (PET). The aim of this study was to determine whether PET-CT with (18)F-FMT provides additional information for the preoperative diagnostic workup as compared with (18)F-FDG PET. PET-CT studies with (18)F-FMT and (18)F-FDG were performed as a part of the preoperative workup in 36 patients with histologically confirmed bronchial carcinoma, 6 patients with benign lesions and a patient with atypical carcinoid. Expression of L-type amino acid transporter 1 (LAT1), CD98, Ki-67 labeling index, VEGF, CD31 and CD34 of the resected tumors were analyzed by immunohistochemical staining, and correlated with the uptake of PET tracers. For the detection of pulmonary malignant tumors, (18)F-FMT PET exhibited a sensitivity of 84% whereas the sensitivity for (18)F-FDG PET was 89% (p = 0.736). (18)F-FMT PET-CT and (18)F-FDG PET-CT agreed with pathological staging in 85 and 68%, respectively (p = 0.151). (18)F-FMT uptake was closely correlated with LAT1, CD98, cell proliferation and angiogenesis. The specificity of (18)F-FMT PET for diagnosing thoracic tumors was higher than that of (18)F-FDG PET. Our results suggest that coexpression of LAT1 and CD98 in addition to cell proliferation and angiogenesis is relavant for the progression and metastasis of lung cancer.
L-[3-(18)F]-α-甲基酪氨酸（(18)F-FMT）是一种用于正电子发射断层扫描（PET）的氨基酸示踪剂。本研究的目的是确定与(18)F-FDG PET相比，(18)F-FMT PET-CT在术前诊断检查中是否能提供更多信息。对36例经组织学确诊的支气管癌患者、6例良性病变患者和1例非典型类癌患者进行了术前检查，其中包括(18)F-FMT和(18)F-FDG的PET-CT研究。通过免疫组织化学染色分析切除肿瘤的L型氨基酸转运体1（LAT1）、CD98、Ki-67标记指数、血管内皮生长因子（VEGF）、CD31和CD34的表达，并与PET示踪剂的摄取情况进行相关性分析。对于肺部恶性肿瘤的检测，(18)F-FMT PET的灵敏度为84%，而(18)F-FDG PET的灵敏度为89%（p = 0.736）。(18)F-FMT PET-CT和(18)F-FDG PET-CT与病理分期的符合率分别为85%和68%（p = 0.151）。(18)F-FMT摄取与LAT1、CD98、细胞增殖和血管生成密切相关。(18)F-FMT PET诊断胸部肿瘤的特异性高于(18)F-FDG PET。我们的结果表明，除了细胞增殖和血管生成外，LAT1和CD98的共表达与肺癌的进展和转移相关。
